CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-12 | Hippel James Chief Financial Officer | Option exercise | +10,000 | $106.59 | $1.1M | 19,137 |
| 2021-02-12 | Hippel James Chief Financial Officer | Sale | −9,400 | $400.32 | $3.8M | 9,737 |
| 2021-02-12 | Hippel James Chief Financial Officer | Sale | −600 | $401.52 | $241K | 9,137 |
| 2021-02-12 | Hippel James Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −10,000 | 39,942 | ||
| 2021-02-12 | Furlow Brenda S. SVP - General Counsel | Option exercise | +10,000 | $106.59 | $1.1M | 16,124 |
| 2021-02-12 | Furlow Brenda S. SVP - General Counsel | Sale | −6,674 | $398.40 | $2.7M | 9,450 |
| 2021-02-12 | Furlow Brenda S. SVP - General Counsel | Sale | −3,326 | $399.12 | $1.3M | 6,124 |
| 2021-02-12 | Furlow Brenda S. SVP - General Counsel | Option exercise · Stock Options (Right to Buy) | −10,000 | 3,538 | ||
| 2021-02-08 | Nusse Roeland Director | Option exercise | +1,000 | $70.35 | $70K | 7,765 |
| 2021-02-08 | Nusse Roeland Director | Option exercise | +5,000 | $66.90 | $335K | 12,765 |
| 2021-02-08 | Nusse Roeland Director | Sale | −6,000 | $385.08 | $2.3M | 6,765 |
| 2021-02-08 | Nusse Roeland Director | Option exercise · Stock Option (right to buy) | −1,000 | 4,000 | ||
| 2021-02-08 | Nusse Roeland Director | Option exercise · Stock Option (right to buy) | −5,000 | 0 | ||
| 2021-02-05 | Kelderman Kim Pres. Diagnostics & Genom | Sale | −823 | $388.45 | $320K | 845 |
| 2021-02-05 | Eansor Norman David President-Protein Sciences | Option exercise | +14,114 | $106.59 | $1.5M | 15,432 |
| 2021-02-05 | Eansor Norman David President-Protein Sciences | Option exercise | +18,819 | $106.59 | $2.0M | 34,251 |
| 2021-02-05 | Eansor Norman David President-Protein Sciences | Sale | −6,000 | $378.29 | $2.3M | 28,251 |
| 2021-02-05 | Eansor Norman David President-Protein Sciences | Sale | −4,500 | $379.62 | $1.7M | 23,751 |
| 2021-02-05 | Eansor Norman David President-Protein Sciences | Sale | −12,833 | $380.50 | $4.9M | 10,918 |
| 2021-02-05 | Eansor Norman David President-Protein Sciences | Sale | −2,900 | $381.52 | $1.1M | 8,018 |
Page 35 of 53 · 1,043 trades